PTGS2 and MMP9 had the highest amplification rates, with DCRGs amplified in bladder cancer, esophagogastric cancer, ovarian cancer, head and neck cancer, and breast cancer (Figure 5D). This evidence concerns the gene MMP9 and urinary bladder carcinoma.